ASO Practice Guidelines Series: Management of Resectable, Borderline Resectable, and Locally Advanced Pancreas Cancer

Ann Surg Oncol. 2024 Mar;31(3):1884-1897. doi: 10.1245/s10434-023-14585-y. Epub 2023 Nov 19.

Abstract

Pancreatic adenocarcinoma is an aggressive disease marked by high rates of both local and distant failure. In the minority of patients with potentially resectable disease, multimodal treatment paradigms have allowed for prolonged survival in an increasingly larger pool of well-selected patients. Therefore, it is critical for surgical oncologists to be abreast of current guideline recommendations for both surgical management and multimodal therapy for pancreas cancer. We discuss these guidelines, as well as the underlying data supporting these positions, to offer surgical oncologists a framework for managing patients with pancreatic adenocarcinoma.

Keywords: Localized pancreatic cancer; Multimodality therapy; Pancreatic cancer guidelines.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma* / surgery
  • Combined Modality Therapy
  • Humans
  • Neoadjuvant Therapy
  • Pancreatic Neoplasms* / surgery